MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2-breast cancer, after chemotherapy for advanced disease Meeting Abstract

  

Authors:	Dickler, M. N.; Tolaney, S. M.; Rugo, H. S.; Cortes, J.; Dieras, V.; Patt, D. A.; Wildiers, H.; Frenzel, M.; Koustenis, A.; Baselga, J.
Abstract Title:	MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2-breast cancer, after chemotherapy for advanced disease
Meeting Title:	52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	34
Issue:	15 Suppl.
Meeting Dates:	2016 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2016-05-20
Start Page:	11s
Language:	English
ACCESSION:	WOS:000404665400017
DOI:	10.1200/JCO.2016.34.15_suppl.510
PROVIDER:	wos
Notes:	Meeting Abstract: 510 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/154919